Dencatistat

Dencatistat
Clinical data
Other namesSTP938
Identifiers
  • 4-[2-(cyclopropylsulfonylamino)pyrimidin-4-yl]-N-[5-(6-ethoxypyrazin-2-yl)-2-pyridinyl]oxane-4-carboxamide
CAS Number
PubChem CID
UNII
ChEMBL
Chemical and physical data
FormulaC24H27N7O5S
Molar mass525.58 g·mol−1
3D model (JSmol)
  • CCOC1=NC(=CN=C1)C2=CN=C(C=C2)NC(=O)C3(CCOCC3)C4=NC(=NC=C4)NS(=O)(=O)C5CC5
  • InChI=InChI=1S/C24H27N7O5S/c1-2-36-21-15-25-14-18(28-21)16-3-6-20(27-13-16)30-22(32)24(8-11-35-12-9-24)19-7-10-26-23(29-19)31-37(33,34)17-4-5-17/h3,6-7,10,13-15,17H,2,4-5,8-9,11-12H2,1H3,(H,26,29,31)(H,27,30,32)
  • Key:WVCJRTCHVUNXST-UHFFFAOYSA-N

Dencatistat is an investigational new drug that is being evaluated by Step Pharma for the treatment of essential thrombocythemia, B-cell lymphoma, and T-cell lymphoma. It is a CTPS1 enzyme inhibitor.

Clinical trials

Dencatistat is currently under clinical trials for lymphomas, solid tumors, and essential thrombocythemia.

References

  1. ↑ "Dencatistat". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
  2. ↑ Parker A (November 2020). "STP938, a Novel, Potent and Selective Inhibitor of CTP Synthase 1 (CTPS1) Is a Targeted Therapy Specifically Blocking De Novo Nucleotide Synthesis in Lymphomas and Leukemias". Blood. 136 (Supplement 1): 31. doi:10.1182/blood-2020-138436.
  3. ↑ "A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas". ClinicalTrials.gov. U.S. National Library of Medicine. Clinical trial record for NCT05463263. Retrieved 5 July 2026.
  4. ↑ "Study of STP938 (Dencatistat) in Advanced Solid Tumours". ClinicalTrials.gov. U.S. National Library of Medicine. Clinical trial record for NCT06297525. Retrieved 5 July 2026.
  5. ↑ "A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial". ClinicalTrials.gov. U.S. National Library of Medicine. Clinical trial record for NCT06786234. Retrieved 5 July 2026.